79 related articles for article (PubMed ID: 8900476)
1. Strength of binding between leukemic blasts and cytotoxic lymphocytes.
Palucka AK; Waniewski J; Porwit A
Cytometry; 1996 Apr; 23(4):330-6. PubMed ID: 8900476
[TBL] [Abstract][Full Text] [Related]
2. Conjugate formation by leukemic blasts from acute myeloid leukemia with cytotoxic lymphocytes.
Palucka AK; Porwit A; Reizenstein P
Leuk Lymphoma; 1993 Nov; 11(5-6):427-33. PubMed ID: 7907248
[TBL] [Abstract][Full Text] [Related]
3. In vitro and in vivo susceptibility of human leukemic cells to lymphokine activated killer activity.
Fierro MT; Liao XS; Lusso P; Bonferroni M; Matera L; Cesano A; Lista P; Arione R; Forni G; Foa R
Leukemia; 1988 Jan; 2(1):50-4. PubMed ID: 3257539
[TBL] [Abstract][Full Text] [Related]
4. Increased susceptibility to lymphokine activated killer (LAK) lysis of relapsing vs. newly diagnosed acute leukemic cells without changes in drug resistance or in the expression of adhesion molecules.
Arienti F; Gambacorti-Passerini C; Borin L; Rivoltini L; Orazi A; Pogliani EM; Corneo G; Parmiani G
Ann Oncol; 1992 Feb; 3(2):155-62. PubMed ID: 1606087
[TBL] [Abstract][Full Text] [Related]
5. Antileukemia activity of a natural killer cell line against human leukemias.
Yan Y; Steinherz P; Klingemann HG; Dennig D; Childs BH; McGuirk J; O'Reilly RJ
Clin Cancer Res; 1998 Nov; 4(11):2859-68. PubMed ID: 9829753
[TBL] [Abstract][Full Text] [Related]
6. Lysis of fresh leukemic blasts by interferon-activated human natural killer cells.
Pattengale PK; Sundstrom C; Yu AL; Levine A
Nat Immun Cell Growth Regul; 1983-1984; 3(4):165-80. PubMed ID: 6597341
[TBL] [Abstract][Full Text] [Related]
7. Binding of leukaemic blasts to various subpopulations of lymphokine-activated killer cells.
Palucka AK; Porwit A; Reizenstein P
Scand J Immunol; 1993 Feb; 37(2):179-85. PubMed ID: 7679523
[TBL] [Abstract][Full Text] [Related]
8. An Hsp70 peptide initiates NK cell killing of leukemic blasts after stem cell transplantation.
Gross C; Holler E; Stangl S; Dickinson A; Pockley AG; Asea AA; Mallappa N; Multhoff G
Leuk Res; 2008 Apr; 32(4):527-34. PubMed ID: 17543383
[TBL] [Abstract][Full Text] [Related]
9. Expansion of natural killer cells with lytic activity against autologous blasts from adult and pediatric acute lymphoid leukemia patients in complete hematologic remission.
Torelli GF; Guarini A; Maggio R; Alfieri C; Vitale A; Foà R
Haematologica; 2005 Jun; 90(6):785-92. PubMed ID: 15951291
[TBL] [Abstract][Full Text] [Related]
10. Defective lymphokine-activated killer cell generation and activity in acute leukemia patients with active disease.
Foa R; Fierro MT; Cesano A; Guarini A; Bonferroni M; Raspadori D; Miniero R; Lauria F; Gavosto F
Blood; 1991 Aug; 78(4):1041-6. PubMed ID: 1868239
[TBL] [Abstract][Full Text] [Related]
11. Clinical grade expansion of CD45RA, CD45RO, and CD62L-positive T-cell lines from HLA-compatible donors: high cytotoxic potential against AML and ALL cells.
Barbui AM; Borleri G; Conti E; Ciocca A; Salvi A; Micò C; Introna M; Rambaldi A
Exp Hematol; 2006 Apr; 34(4):475-85. PubMed ID: 16569594
[TBL] [Abstract][Full Text] [Related]
12. Resistance of some leukemic blasts to lysis by lymphokine activated killer (LAK) cells.
Panayotides P; Porwit A; Sjögren AM; Wasserman J; Reizenstein P
Eur J Haematol; 1988 Apr; 40(4):362-7. PubMed ID: 3259192
[TBL] [Abstract][Full Text] [Related]
13. Characterization of cord blood natural killer and lymphokine activated killer lymphocytes following ex vivo cellular engineering.
Ayello J; van de Ven C; Fortino W; Wade-Harris C; Satwani P; Baxi L; Simpson LL; Sanger W; Pickering D; Kurtzberg J; Cairo MS
Biol Blood Marrow Transplant; 2006 Jun; 12(6):608-22. PubMed ID: 16737934
[TBL] [Abstract][Full Text] [Related]
14. Kinetic analysis of cytotoxic lymphocyte-target cell interaction as quantified by dual parameter flow cytometry.
Waniewski J; Palucka AK; Porwit A
Cytometry; 1993; 14(4):393-400. PubMed ID: 8513695
[TBL] [Abstract][Full Text] [Related]
15. [Expression of CD16zeta in NK cells of B-cell non-Hodgkin's lymphoma patients and in vitro killing effect of rituximab combined lymphokine-activated killer cells on B-NHL cells].
Shi YX; Zhang XS; Xia JC; Li YQ; Xu RH; Han WJ; Zhang JH; Guan ZZ; Jiang WQ
Ai Zheng; 2007 Aug; 26(8):837-42. PubMed ID: 17697543
[TBL] [Abstract][Full Text] [Related]
16. Lymphokine-activated killer (LAK) cells inhibit the clonogenic growth of human leukemic stem cells.
Lista P; Fierro MT; Liao XS; Bonferroni M; Brizzi MF; Porcu P; Pegoraro L; Foa R
Eur J Haematol; 1989 May; 42(5):425-30. PubMed ID: 2786477
[TBL] [Abstract][Full Text] [Related]
17. [Killing activity of lymphokine-activated killer (LAK) cells on fresh acute leukemia cells].
Zhao TH
Zhonghua Zhong Liu Za Zhi; 1991 Mar; 13(2):117-9. PubMed ID: 1879289
[TBL] [Abstract][Full Text] [Related]
18. A cytotoxic NK-cell line (NK-92) for ex vivo purging of leukemia from blood.
Klingemann HG; Wong E; Maki G
Biol Blood Marrow Transplant; 1996 May; 2(2):68-75. PubMed ID: 9118301
[TBL] [Abstract][Full Text] [Related]
19. [Morphological observation on NK/LAK cell-mediated lysis of human oral carcinoma cells].
Zheng YJ; Zhang J; Wang SM; Zhang JR
Di Yi Jun Yi Da Xue Xue Bao; 2004 Apr; 24(4):392-6. PubMed ID: 15090306
[TBL] [Abstract][Full Text] [Related]
20. Activation of autologous leukemia-specific T cells in acute myeloid leukemia: monocyte-derived dendritic cells cocultured with leukemic blasts compared with leukemia-derived dendritic cells.
Draube A; Beyer M; Wolf J
Eur J Haematol; 2008 Oct; 81(4):281-8. PubMed ID: 18573171
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
